Cenplacel-l clinical trials
Also written PDA001.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses cenplacel-l is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PDA001
- 2
Studies by the year they started
5 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Avoplacel (1)
Studies
Open first, then newest update. How each study uses cenplacel-l is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell TransplantationCompletedPhase 1Pluristem Ltd.NCT03002519Written as PLX-R18
- Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid ArthritisTerminatedPhase 2Celularity IncorporatedNCT01261403Written as PDA001
- A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's DiseaseCompletedPhase 1Celularity IncorporatedNCT01769755Written as PDA001
- Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary SarcoidosisTerminatedPhase 1Celularity IncorporatedNCT01440192Written as PDA001 (cenplacel-L)
- Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic StrokeTerminatedPhase 2Celularity IncorporatedNCT01310114Written as Human Placenta-Derived Cells PDA001- (cenplacel-L)
Codes
What other systems call cenplacel-l · ClinicalTrials.gg INT017492
- UNII (FDA) OOH12XV6XRCENPLACEL-LOne source FDA
- NCI Thesaurus C171653Cenplacel-LOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OOH12XV6XR | CENPLACEL-L | One source FDA |
| NCI Thesaurus | C171653 | Cenplacel-L | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.